Denali Therapeutics Inc (NASDAQ:DNLI) – Equities researchers at Wedbush lifted their FY2019 earnings per share estimates for shares of Denali Therapeutics in a report issued on Thursday, November 7th. Wedbush analyst L. Chico now expects that the company will earn ($2.18) per share for the year, up from their prior estimate of ($2.34). Wedbush has a “Neutral” rating and a $19.00 price target on the stock. Wedbush also issued estimates for Denali Therapeutics’ Q1 2020 earnings at ($0.65) EPS and FY2020 earnings at ($2.62) EPS.
A number of other equities research analysts also recently weighed in on DNLI. BTIG Research initiated coverage on Denali Therapeutics in a report on Friday, August 9th. They set a “buy” rating and a $30.00 target price for the company. Zacks Investment Research downgraded Denali Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 7th. Nomura started coverage on Denali Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $35.00 price target for the company. ValuEngine raised Denali Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Finally, Morgan Stanley set a $32.00 price target on Denali Therapeutics and gave the company a “buy” rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. Denali Therapeutics has an average rating of “Buy” and an average target price of $27.43.
Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.48) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.08. Denali Therapeutics had a negative return on equity of 13.37% and a negative net margin of 44.73%. The company had revenue of $13.60 million during the quarter, compared to the consensus estimate of $10.86 million.
In other news, COO Alexander O. Schuth sold 7,500 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.16, for a total transaction of $136,200.00. Also, CEO Ryan J. Watts sold 8,581 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $18.05, for a total value of $154,887.05. Following the sale, the chief executive officer now owns 12,505 shares in the company, valued at $225,715.25. The disclosure for this sale can be found here. Insiders own 21.20% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its holdings in shares of Denali Therapeutics by 1,721.7% during the third quarter. Tower Research Capital LLC TRC now owns 2,095 shares of the company’s stock worth $32,000 after purchasing an additional 1,980 shares during the last quarter. Bank of Montreal Can bought a new stake in Denali Therapeutics in the second quarter valued at approximately $83,000. Xact Kapitalforvaltning AB bought a new stake in Denali Therapeutics in the second quarter valued at approximately $210,000. AQR Capital Management LLC bought a new stake in Denali Therapeutics in the second quarter valued at approximately $215,000. Finally, Acadian Asset Management LLC boosted its holdings in Denali Therapeutics by 136.7% in the second quarter. Acadian Asset Management LLC now owns 11,650 shares of the company’s stock valued at $241,000 after acquiring an additional 6,728 shares during the last quarter. Institutional investors own 74.09% of the company’s stock.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.